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Ovulation is believed to contribute to the development of ovarian cancers that derive from the ovarian surface epithelium (OSE).
The process of ovulation is synonymous with inflammation and inflammatory cytokines such as interleukin-1a (IL-1a) have recently
been shown to induce both inflammatory and anti-inflammatory responses in human OSE (HOSE) cells. In this study we directly
compared levels of IL-1a-induced gene expression by analysing the levels of 11b-hydroxysteroid dehydrogenase (11bHSD) types 1
(11bHSD-1) and 2 (11bHSD-2), cyclooxygenase-2 (COX-2), IL-1 receptor (IL-1R) and glucocorticoid receptor a (GRa) mRNA
between normal HOSE cells and cell lines derived from poorly differentiated (SKOV-3, BG-1, PEO-4) and well-differentiated
(PEO-14) ovarian adenocarcinoma. In HOSE cell cultures, and to a lesser extent PEO-14 cells, the basal mRNA levels of COX-2
and 11bHSD-1 were relatively high and further shown to be induced in response to IL-1a (for HOSE cells; 420-fold, Po0.05 and
PEO-14 cells; 43fold, Po0.05). However, whereas HOSE cells expressed a low level of 11bHSD-2 mRNA that was only mildly
responsive to IL-1a (1.3-fold, Po0.001), all cell lines exhibited a higher basal level of 11bHSD-2 mRNA that was in some cases
further stimulated in PEO-4 cells (five-fold; Po0.05) or suppressed in SKOV-3 cells (two-fold; Po0.01) in response to IL-1a. All cells
tested expressed IL-1R and, with the exception of BG-1, GRa. These results indicate that cell lines derived from ovarian cancers have
lost the ability to respond normally to inflammatory cytokines such as IL-1a. The finding that normal OSE cells, in contrast to cell lines
derived from patients with ovarian adenocarcinoma, abundantly express 11bHSD-1 mRNA but are essentially devoid of 11bHSD-2
mRNA supports the concept that the pattern of 11bHSD isoform gene expression is a defining feature of neoplastic cellular
transformation, which might have particular relevance to the ovary.
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The surface of the ovary is covered by a continuous layer of
cuboidal epithelial cells known as the ovarian surface epithelium
(OSE). Although human OSE (HOSE) cells have been collected,
cultured and studied in vitro, their natural function beyond
forming a physical barrier between ovary and other peritoneal
surfaces is unclear (Auersperg et al, 2001). The OSE cell layer,
however, would appear to be important for ovulation since
ovulation does not proceed in its absence (Colgin and Murdoch,
1997). Repeated episodes of ovulation-associated injury and repair
are presumed to underlie the high frequency of ovarian carcinoma
arising from the OSE (Fathalla, 1971; Salazar et al, 1996), which
account for 90% of all ovarian cancers (Ozols, 1991). Since
ovulation is a natural inflammatory process (Espey, 1980a,b),
factors related to inflammation of the OSE have been associated
with increased risk of ovarian cancer (Ness and Cottreau, 1999;
Ness et al, 2000). It is therefore critically important to understand
how inflammatory cell damage is normally resolved in the OSE.
The inflammatory response at ovulation induces extensive tissue
remodelling (Murdoch et al, 1999; Bukulmez and Arici, 2000) and
accompanying cell death that is observed within OSE cells
(Murdoch et al, 1999). Mutations responsible for generating
cancerous cells are believed to arise from DNA replication/repair
errors during subsequent rounds of OSE cell proliferation. The rate
of mutation is further believed to increase in the presence of toxic
oxidants that are released during such an inflammatory response
(Ness and Cottreau, 1999).
In patients with ovarian cancer, increased levels of IL-1 and IL-1R
are present in serum (Zeisler et al, 1998; Kondera-Anasz et al, 2003).
These levels, however, are suggested to arise as a consequence of
ovarian cancer, rather than playing any causal role (Punnonen
et al, 1991; Kutteh and Kutteh, 1992). This is further exemplified by
the positive effect of IL-1a treatment in patients with ovarian
cancer (Buescher et al, 1993; Lee et al, 1993; Vadhan-Raj et al,
1994; Verschraegen et al, 1996). A closer look at the IL-1a gene in
cancer patients showed no association with polymorphisms (Hefler
et al, 2002). However, polymorphism of the interleukin receptor
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santagonist (IL-1RA) gene was shown to be associated with ovarian
cancer (Sehouli et al, 2003a,b, 2002). In patients with ovarian
cancer, IL-1RA is present at increased levels (Burger et al, 1994;
Fujiwaki et al, 1997; Kondera-Anasz et al,2 0 0 3 ) .M o r ed e t a i l e d
studies on the role of IL-1a in ovarian cancer have produced
conflicting results. Thus, while IL-1 is reported to increase ovarian
cancer cell growth in an autocrine fashion (Marth et al, 1996;
Huleihel et al, 1997; Kawakami et al, 1997), IL-1 is documented to
enhance ovarian cancer cell death and inhibit cellular repair
mechanisms (Benchekroun et al, 1995; Wang et al, 1996).
Interleukin-1, the prototypical inflammatory cytokine known
to be produced in association with ovulation is documented to
stimulate inflammatory changes in primary HOSE cell cultures,
measured as increased gene expression of cyclooxygenase-2 (COX-
2) (Rae et al, 2004) and matrix metalloproteinases (Niven et al,
2004). IL-1a also simultaneously induces increased expression and
activity of 11b-hydroxysteroid dehydrogenase type 1 (11bHSD-1)
in HOSE cells (Yong et al, 2002). 11bHSD-1 is a steroid
dehydrogenase/reductase enzyme that reversibly promotes in-
creased formation of cortisol from substrate cortisone (Tannin
et al, 1991; Stewart and Mason, 1995). The local increase of cortisol
is believed to play a role in providing an anti-inflammatory
environment to counteract inflammation caused at ovulation
(Andersen and Hornnes, 1994; Escher et al, 1997; Hillier and
Tetsuka, 1998; Yong et al, 2002; Rae et al, 2004). In addition to
11bHSD-1, an additional 11bHSD isoform, 11bHSD-2, converts
cortisol to cortisone; reviewed in Michael et al (2003). Although
inflammatory stimulation appears not to alter expression of
11bHSD-2 in HOSE cells (Rae et al, 2004), an increased level of
11bHSD-2 is present within tumors that originate from breast,
colon, adipose, adrenal and pituatory tissue (Rabbitt et al, 2003).
Here we directly compared the levels of gene expression of
COX-2, 11bHSD-1 and -2 in response to treatment with IL-1a in
normal HOSE cells and a series of cell lines derived from the ovaries
of patients with ovarian adenocarcinoma (Langdon et al, 1988).
MATERIALS AND METHODS
Isolation of HOSE cells
HOSE cells were obtained with informed consent after local ethical
committee approval from the ovaries of premenopausal women
undergoing elective surgery for nonmalignant gynaecological
conditions. Cells were collected at laparotomy by gentle scraping
of the ovarian surface with a sterile wooden spatula, which was
then rinsed into sterile, warmed HOSE1 culture media (see below).
Cells were collected as near to the beginning of surgical procedure
as practicable to avoid any contamination with blood cells.
Collections were then examined by phase-contrast microscopy to
ensure that sufficient flakes of OSE had been obtained and cultured
in donor calf serum-precoated flasks (75cm
2, Corning Inc., Glass
Works, Corning NY, USA).
Culture of HOSE cells
Culture media (HOSE 1) consisted of Medium199:MCDB105
(1:1vv
 1) supplemented with foetal calf serum (15%vv
 1),
streptomycin (50mgml
 1), penicillin (50IUml
 1) and L-glutamine
(1mmoll
 1) (8). Cells were incubated at 371C in a humidified
incubator under an atmosphere of 95% air, 5% CO2 for up to 28
days, with media renewed every 7 days. Confluent cell monolayers
were routinely obtained in 21 days using this system. Monolayers
were routinely examined by phase-contrast microscopy for
contaminating cells such as fibroblasts, and confirmation of cell
purity was confirmed in selected cases with immunocytochemical
staining for cytokeratin 7, 8, 18 and 19 (Czernobilsky, 1985; van
Niekerk et al, 1991) using a commercially available monoclonal
anti-human cytokeratin antibody (Dako), which revealed that
monolayers were pure epithelial cells using this culture system
(data not shown). Confluent HOSE monolayers were treated with
trypsin-EDTA in Hanks balanced salt solution (0.05% wv
 1
trypsin, 0.5mM EDTA, Invitrogen) at 371C for 5min. Cells were
then collected by centrifugation at 800g for 5min. This pellet was
washed in fresh HOSE 1 media, and then resuspended in fresh
media. Cell number and viability were determined by trypan blue
(Sigma) exclusion counting in a haemocytometer; viability ranged
from 75 to 95%. HOSE cells were seeded in six-well plates
(50000well
 1) and incubated with HOSE 1 medium for 48h. For
treatments, HOSE cells were incubated for a further 24h in
Dulbecco’s modified Eagle’s medium nutrient F-12, containing
100Uml
 1 penicillin, 100mgml
 1 streptomycin (as used for cell
lines) and subsequently treated with 0.25, 0.5 or 1ngml
 1 IL-1a
(R&D Systems Europe Ltd, Abingdon, Oxon, UK) for a further
48h. All tissue culture reagents were obtained from Gibco BRL
(Life technologies Ltd, Renfrewshire, UK) and Sigma Chemical Co.
(Poole, Dorset, UK).
Cell lines
The following cell lines SKOV-3, BG-1, PEO-4 and PEO-14 were
kindly provided by P Pujol, INSERM, Montpellier, France. Cells
were routinely grown in complete medium (Dulbecco’s modified
Eagle’s medium nutrient F-12, containing 100Uml
 1 penicillin,
100mgml
 1 streptomycin and 10% foetal calf serum). The cell lines
were seeded in six-well plates (50000cellswell
 1) and incubated
with serum-free medium for 24h. The cells were subsequently
treated with 0.25, 0.5 or 1ngml
 1 IL-1a (R&D Systems Europe Ltd,
Abingdon, Oxon, UK) for a further 48h.
RNA extraction and quality analysis
RNA was extracted from HOSE cells using RNeasy minispin
columns (Qiagen) as per manufacturer’s protocol. In total, 1ml
aliquots of purified RNA were removed for quantification and
quality assessment. RNA was quantified and quality assessed using
the Agilent 2100 Bioanalyser system for total RNA in combination
with RNA6000nano chips (Agilent Technologies, Cheshire, UK).
Only RNA that displayed intact 18S and 28S peaks was reverse
transcribed to cDNA for PCR analysis. This quality control step
was included for each experimental run to avoid generation of false
negative results due to RNA degradation prior to and during
extraction steps, and also as a quantification method to ensure
equal amounts of RNA were transcribed in each RT- reaction.
Real-time PCR analysis
Total RNA (1mg) was treated with DNAase (Invitrogen) as per the
manufacturer’s protocol. In total, 200ng treated RNA was reverse
transcribed (random hexamer kit; Applied Biosystems), and 2ml
of the RT-mix was analysed. cDNA was analysed in a 25ml final
volume assay system containing 300nmoll
 1 primers and
200nmoll
 1 TaqMan hybridisation probe (Biosource UK Ltd).
Primers and probes were designed using Primer-Express software
(Perkin-Elmer), where possible spanning intron regions to avoid
any poterntial of genomic DNA amplification. For human
11bHSD-1, the following was used: forward primer (AGG ATC
TTC CTG CAT GGA TTT C), reverse primer (AGC TCT GCG CCA
AGA AGA AGT) and probe (TGA CAG CTC ACT CTG GAC CAC
TCT TCT GA). For human 11bHSD-2, the following was used:
forward primer (GGC CAA GGT TTC CCA GTG A), reverse primer
(GTT GTG CCA GGA GGG TGT TT) and probe (CTC TGC GCC
TCT CCA CTG TTT CAT GA). For human COX-2, the following
was used: forward primer (CCT TCC TCC TGT GCC TGA TG),
reverse primer (ACA ATC TCA TTT GAA TCA GGA AGC T) and
probe (TGC CCG ACT CCC TTG GGT GTC A). For human IL-1R
(type 1), the following was used: forward primer (TGT CAC CGG
Inflammation-associated gene expression
O Gubbay et al
1928
British Journal of Cancer (2005) 92(10), 1927–1933 & 2005 Cancer Research UK
G
e
n
e
t
i
c
s
a
n
d
G
e
n
o
m
i
c
sCCA GTT GAG T), reverse primer (GCA CTG GGT CAT CTT CAT
CAATT) and probe (ACA TTG CTT ACT GGA AGT GGA ATG
GGT CAG). Target mRNA was quantified in relation to 18S
ribosomal RNA abundance in each sample, with suitable positive
control RNA (human liver total RNA from Ambion and in house
prepared human placental mRNA). Negative controls included
RT-negative samples (RNA template with no reverse transcriptase
enzyme), RT-H2O (water in place of RNA template) samples
generated at the time of reverse transcription of samples and a
Taqman reaction negative control where cDNA was replaced with
water. Primer and probe sets for COX-2 were the kind gifts of Dr H
Jabbour (HRSU, Medical Research Council, Edinburgh, UK). Data
are presented relative to 18S as mean7s.e.m. and statistics
performed using the superANNOVA package from Abacus
Concepts, Inc.
Analysis of RT–PCR by agarose gel electrophoresis
Reverse transcription reactions were conducted in a volume of
50ml consisting of 2mg of total RNA, 10ng oligo-dT (Gibco
Invitrogen Corporation), 0.01 M DTT, 1mM dNTPs and Superscript
reverse transcriptase (Gibco Invitrogen Corporation). PCR was
performed in 25ml reactions, containing 2ml of the reverse
transcription reaction with reagents provided by Hybaid UK
including 10% dimethyl sulphoxide. PCR samples were heated at
941C for 2min, followed by 30 cycles of 941C for 30s, 551C for 30s
and 721C for 30s, and an extension time of 5min at 721C. The
following primers were used in PCR reactions (20pmol per
reaction): human IL-1 (type 1) receptor (forward: ATC TAC AGA
ACA AGC CTC CAG G and reverse: CCA CAC TGT AAT AGT CTT
CC), human 11bHSD-1 (forward: TGT AGG TTC TCT CTG TGT
GTC C and reverse: GCA AAT GTT AGA GGA ACT CC), human
11bHSD-2 (forward: GTA TTG GAG TTG AAC AGC CCC G and
reverse: AGA GAC ACT TGG GAT TTA GCC C) and human COX-2
(forward: CGA GGT GTA TGT ATG AGT GTG G and reverse: GCA
ATC ATC AGG CAC AGG), human GRa sense (forward: ACA CAG
GCT TCA GGT ATC TT and reverse: ACT GCT TCT GTT GCC
AAG). PCR fragments were visualised by ethidium bromide
staining on 1% agarose gels.
RESULTS
mRNA analysis of cancer cell lines and HOSE cells
In order to compare levels of gene expression between HOSE cells
and cancer cell lines, RNA was isolated and analysed by RT–PCR
either by agarose gel electrophoresis (Figure 1) or real-time PCR
(Figure 2). For HOSE cells, levels of 11bHSD-1, COX-2, IL-1
receptor (IL-1R) and glucocorticod receptor a (GRa) mRNA were
easily detected; however, 11bHSD-2 mRNA was barely detected.
In contrast, all four cancer cell lines showed significantly lower
levels of 11bHSD-1 mRNA but higher levels of 11bHSD-2, relative
to HOSE cells. Whereas PEO-14 cells exhibited patterns of COX-2
and IL-1R mRNA expression similar to that of HOSE cells, these
two genes were expressed at much lower levels in SKOV-3, BG-1
and PEO-4 cells. With the exception of BG-1 cells, GRa mRNA was
readily detected in all cells.
Effect of IL-1a on 11bHSD-1 mRNA in cancer cell lines and
HOSE cells
Treatment of HOSE cells with IL-1a dramatically enhanced the
level of 11bHSD-1 mRNA up to 28-fold (Po0.01) in a dose-
dependant fashion (Figure 3). In contrast, with the exception of
PEO-14 cells, IL-1a did not alter the level of 11bHSD-1 mRNA in
the other cell lines tested. For PEO-14 cells, a maximal three-fold
induction of 11bHSD-1 mRNA was observed in response to
1ngml
 1 IL-1a (Po0.01).
Effect of IL-1a on 11bHSD-2 mRNA in cancer cell lines and
HOSE cells
The level of 11bHSD-2 mRNA in HOSE cells was unaffected by the
presence of IL-1a except for marginal stimulation in response to
1ngml
 1 IL-1a (1.6-fold; Po0.001), see Figure 4. The greatest
stimulation of 11bHSD-2 mRNA level was observed in PEO-4 cells
treated with 0.5ngml
 1 IL-1a (4.6-fold; Po0.05). For BG-1 and
PEO-14 cells, 11bHSD-2 mRNA level was similarly observed to
increase in response to IL-1a; however, this was not significant. In
contrast, addition of IL-1a to SKOV-3 cells induced a significant
decrease of 11bHSD-2 mRNA level (two-fold; Po0.01).
Effect of IL-1a on COX-2 mRNA in cancer cell lines and
HOSE cells
Treatment of HOSE cells with IL-1a dramatically increased the
level of COX-2 mRNA in a dose-dependant fashion exhibiting
maximal stimulation with 1ngml
 1 IL-1a (28-fold; Po0.001), see
Figure 5. In contrast, the level of COX-2 mRNA in the cell lines was
largely unaffected; only a mild stimulation was observed in
response to 1ngml
 1 IL-1a in either SKOV-3 or PEO-14 cells
(2.8-fold, Po0.05).
DISCUSSION
This study reveals unique immuno-endocrine signatures for four
ovarian adenocarcinoma cell lines (SKOV-3, BG-1, PEO-4 and
PEO-14) that clearly distinguish them from the nontransformed
HOSE cell type from which most ovarian cancers are presumed to
derive. Whereas primary HOSE cell cultures show highly IL-1a
responsive COX-2 and 11bHSD-1 gene expression, neither gene in
the cancer cell lines responded markedly to IL-1a. In contrast,
whereas HOSE cells exhibited a low level of 11bHSD-2 mRNA that
was mildly responsive to IL-1a (1.6-fold, Po0.001), all cell lines
exhibited a higher basal level (Po0.01) of 11bHSD-2 mRNA that
was in some cases further stimulated in PEO-4 cells (five-fold;
Po0.05) or suppressed in SKOV-3 cells (two-fold; Po0.01), in
response to IL-1a. Increased expression of COX-2 is a hallmark
of the inflammatory response. The stimulation of COX-2 in
HOSE cells (28-fold, Po0.001) and relative lack of stimulation in
11HSD-1
11HSD-2
COX-2
IL-1R
GR
-Actin
1090 bp
1303 bp
249 bp
646 bp
557 bp
200 bp
HOSE SKOV-3 BG-1 PEO-4 PEO-14
_ + __ _ _ ++ + +
Figure 1 RT–PCR of 11bHSD-1 and -2, COX-2, IL-1 receptor, GRa
and b-actin using RNA isolated from HOSE, SKOV-3, BG-1, PEO-4 and
PEO-14 cells. Reactions were performed in the absence ( ) and presence
(þ) of reverse transcriptase. One example of three separate experiments
is presented.
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sSKOV-3, BG-1 and PEO-4 cancer cell lines, in response to IL-1a,
therefore, suggests that these cancer cell lines have lost the ability to
induce a normal inflammatory response. It remains to be determined
if these findings translate to primary ovarian cancer cells; however,
we consider the data presented here to justify such an analysis if the
ethical and logistical constraints in establishing suitable primary cell
cultures from sufficient patients can be overcome.
Based on the divergent effects of 11bHSD-1 and -2 on cell
proliferation observed in vitro, Rabbitt et al (2003) have previously
suggested that the ability of 11bHSD-1 to generate cortisol might
act as an autocrine antiproliferative, prodifferentiation stimulus in
normal adult tissues. In contrast, the cortisol-inactivating proper-
ties of 11bHSD-2 might lead to pro-proliferative effects, particu-
larly in tumours. Our finding that normal OSE cells, unlike cell
lines derived from ovarian tumours, abundantly express 11bHSD-1
mRNA but are essentially devoid of 11bHSD-2 mRNA, supports
the concept that the pattern of 11bHSD isoform expression is a
defining feature of neoplastic cellular transformation that could
have particular relevance to the ovary.
Based on the level of IL-1R mRNA, the differential effects
observed in response to IL-1a between cell lines and HOSE cells
may simply result from differential IL-1R expression. Although
IL-1R mRNA is more abundant in HOSE cells and PEO-14 cells,
IL-1R mRNA is nevertheless detectable in the other cell lines tested
(Figure 2). The observation that the level of 11bHSD-2 mRNA is
more greatly increased in response to IL-1a in cancer cell lines
relative to HOSE cells (Figure 4) may suggest that expression of
IL-1R is not limiting the effects of IL-1a on gene expression in the
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Figure 2 Real-time PCR using RNA isolated from HOSE, SKOV-3, BG-1,
PEO-4 and PEO-14 cells. Level of mRNA was standardised to 18S using an
internal control and each sample normalised to a reference sample. Data
(n¼4) are presented as fold increase and mean7s.e.m. Letters denote
significance relative to HOSE cells: a: Po0.01 and b: Po0.001.
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Figure 3 Real-time PCR of 11bHSD-1 in HOSE, SKOV-3, BG-1, PEO-4
and PEO-14 cells treated with increasing concentrations of IL-1a. Level of
mRNA was standardised to 18S using an internal control and normalised to
untreated cells. Data (n¼6) are presented as mean7s.e.m. Letters denote
significance above control: a: Po0.05 and b: Po0.01.
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Figure 4 Real-time PCR of 11bHSD-2 in HOSE, SKOV-3, BG-1, PEO-4
and PEO-14 cells treated with increasing concentrations of IL-1a. Level of
mRNA was standardised to 18S using an internal control and normalised to
untreated cells. Data (n¼6) are presented as mean7s.e.m. Letters denote
significance above control: a: Po0.05 and b: Po0.001, and below control:
c: Po0.05 and d: Po0.01.
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scancer cell lines. In the case of SKOV-3, IL-1R signalling was
previously shown to be functional by demonstrating activation of
NF-kappa in response to IL-1b (Bonizzi et al, 1996).
IL-1R signalling is initiated by receptor-associated proteins that
include TRAFs (TNF receptor-associated factors; Inoue et al,
2000), TIRs (Toll IL-1 receptor proteins; McGettrick and O’Neill,
2004) and IRAKs (IL-1 receptor-associated kinases; Janssens and
Beyaert, 2003). IL-1 also activates MAP kinase pathways: p38
(Guan et al, 1997), ERK 1/2 ((Laporte et al, 1999) and JNK (Guan
et al, 1998) and subsequently activates transcription factors such
as NF-kb (Roshak et al, 1996). In addition, modulation of IL-1R
signalling is altered by other signalling proteins such as Smads,
SOCSs (suppressor of cytokine signalling; Yoshimura et al, 2003)
and STATs (Morton et al, 1999). In one study of ovarian
carcinoma, SOCS 1 and 2 genes were demonstrated to be silenced
due to hypermethylation (Sutherland et al, 2004) and a number of
studies have identified increased levels of STAT proteins
(particularly STAT 3) in ovarian cancers (Huang et al, 2000; Chen
et al, 2004; Meinhold-Heerlein et al, 2005; Silver et al, 2004). We
are currently focusing our attention on IL-1R signalling in order to
identify any differences between primary HOSE cells and ovarian
cancer cells.
Although there are clearly differences between all cell lines and
HOSE cells, the PEO-14 cell line appears most closely to resemble
HOSE cells. Relative to SKOV-3, BG-1 and PEO-4 cells, PEO-14 and
HOSE cells express higher levels of 11bHSD-1, COX-2 and IL-1R
mRNA and lower levels of 11bHSD-2 mRNA. Moreover, whereas
11bHSD-2 mRNA is unaltered in response to IL-1a, the level of
11bHSD-1 and COX-2 mRNA is stimulated in response to IL-1a in
both HOSE and PEO-14 cells. The observation that the PEO-14 cell
line most closely resembles HOSE cells is consistent with the origin
of PEO-14 cells from a well-differentiated serous adenocarcinoma;
SKOV-3, BG-1 and PEO-4 cells originate from poorly differentiated
serous adenocarcinoma. Since the cell lines used in this study are
derived from different ovarian cancers at different stages of
differentiation, it is possible that the heterogeneity observed is
reflective of these differences. Indeed, the responses observed may
provide a novel means of defining such differences at a functional
level.
Whereas 11bHSD-1 predominantly catalyses 11-oxoreduction of
cortisone to cortisol, 11bHSD-2 converts cortisol to cortisone. The
pattern of 11bHSD type 1 and 2 expression described in HOSE
cells is therefore consistent with an increased conversion of
cortisone to cortisol upon exposure to IL-1a, previously identified
in HOSE cells (Yong et al, 2002). Thus, upregulation of 11bHSD-1
without a measurable change in 11bHSD-2 would be predicted to
result in increased conversion of systemically derived cortisone to
anti-inflammatory cortisol in the OSE. This is proposed as a
compensatory anti-inflammatory mechanism that accompanies the
inflammatory response (e.g. COX-2 expression) to cytokines
shown by the OSE during LH-induced ovulation in vivo.
Receptors for glucocorticoids are present in tumour cells of
almost 90% of ovarian cancers, and these hormones inhibit ovarian
cancer cell growth (Karlan et al, 1994). It is therefore of interest that
three epithelial cancer cell lines (SKOV-3, BG-1 and PEO-4) exhibit
a low basal level of 11bHSD-1 that is unresponsive to inflammatory
stimulation, yet have gained a basal level of 11bHSD-2 mRNA that,
in the case of the PEO-4 cell line, is cytokine responsive. For HOSE
cells, addition of cortisol augments IL-1a stimulation of 11bHSD-1,
but decreases IL-1a induced COX-2 expression (Rae et al, 2004).
The increased level of cortisol, in response to IL-1a induced
11bHSD-1, is thereby envisaged to function in an anti-inflamma-
tory manner. The impact of glucocorticoids on IL-1a responsive-
ness in ovarian cell lines remains to be assessed; however, it is
interesting to note that unlike HOSE and other cell lines, the BG-1
cell line does not appear to express GRa.
The potential pathophysiological relevance of these findings
relates to the likelihood that serial inflammatory injury associated
with ovulation predisposes the OSE to neoplastic transformation.
Factors related to inflammation of the OSE have been associated
with increased risk of ovarian cancer (Ness and Cottreau, 1999;
Ness et al, 2000) and exposure to anti-inflammatory agents has
been shown to inhibit tumour invasion and protease production
by ovarian carcinoma cells (Akhmedkhanov et al, 2001). It is
therefore of obvious interest that all cell lines studied here appear
to have largely lost their capacity to mount an inflammatory
response to IL-1a in terms of increased 11bHSD-1 expression and
hence increased formation of anti-inflammatory, proapoptotic
glucocorticoids. It remains to be determined whether this loss of
response to proinflammatory cytokines is a feature of the primary
tumours from which ovarian cancer cell lines are derived and
whether it might be causal or consequential to disease progress.
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